nach oben

Erschienen in:

01.08.2012 | Magnetic Resonance

Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI

verfasst von: Timm Denecke, Ingo G. Steffen, Sheela Agarwal, Daniel Seehofer, Thomas Kröncke, Enrique Lopez Hänninen, Incken-Birthe Kramme, Peter Neuhaus, Sanjay Saini, Bernd Hamm, Christian Grieser

Erschienen in: European Radiology | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

The purpose of this study was to evaluate enhancement characteristics of hepatocellular adenomas (HCAs) using gadoxetic acid as a hepatocyte-specific MR contrast agent.

Methods

Twenty-four patients with histopathologically proven HCAs were retrospectively identified. MRI consisted of T1- and T2-weighted (w) sequences with and without fat saturation (fs), multiphase dynamic T1-w images, and fs T1-w images during the hepatobiliary phase. Standard of reference was surgical resection (n = 19) or biopsy (n = 5). Images were analysed for morphology and contrast behaviour including signal intensity (SI) measurement on T1-w images normalised to the pre-contrast base line.

Results

In total 34 HCAs were evaluated. All HCAs showed enhancement in the arterial phase; 38 % of HCAs showed reduced contrast enhancement (“wash-out”) in the venous phase. All HCAs showed enhancement (SI increase, 56 ± 53 %; P <0.001) in the hepatobiliary phase, although liver uptake was stronger (96 ± 58 %). Thus, 31 of all HCAs (91 %) appeared hypointense to the surrounding liver in the hepatobiliary phase, while 3 out of 34 lesions were iso-/hyperintense.

Conclusions

Gadoxetic acid accumulates in HCAs in the hepatobiliary phase, although significantly less than in surrounding liver. Thus, HCA appears in the vast majority of cases as a hypointense lesion on hepatobiliary phase images.

Key Points

• Magnetic resonance-specific contrast agents are now available for hepatic imaging.

• Hepatocellular adenomas enhance with gadoxetic acid as in previous CT/MRI experience.

• Enhancement during the hepatobiliary phase is less in HCAs than in liver.

• Typical HCAs appear as hypointense lesions on T1-w hepatobiliary phase images.

• True hyperintense HCA enhancement can occasionally occur during the hepatobiliary phase.

Soe KL, Soe M, Gluud C (1992) Liver pathology associated with the use of anabolic-androgenic steroids. Liver 12:73–9PubMedCrossRef

van den Esschert JW, van Gulik TM, Phoa SS (2010) Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma. Dig Surg 27:46–55PubMedCrossRef

van der Windt DJ, Kok NF, Hussain SM, Zondervan PE, Alwayn IP, de Man RA et al (2006) Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 93:1495–502PubMedCrossRef

Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV (2011) Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology 258:673–93PubMedCrossRef

Barthelmes L, Tait IS (2005) Liver cell adenoma and liver cell adenomatosis. HPB (Oxford) 7:186–96CrossRef

Stoot JH, Coelen RJ, De Jong MC, Dejong CH (2010) Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 12:509–22CrossRef

Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W (2009) Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 19:342–57PubMedCrossRef

Morana G, Grazioli L, Kirchin MA, Bondioni MP, Faccioli N, Guarise A et al (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46:225–39PubMedCrossRef

Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ et al (2005) Efficacy and safety of MR imaging with liver-specific contrast agent: US multicenter phase III study. Radiology 237:89–98PubMedCrossRef

10.

Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L et al (2006) Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT–a multicenter trial. J Comput Assist Tomogr 30:345–54PubMedCrossRef

11.

Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J et al (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT–initial observations. Radiology 234:468–78PubMedCrossRef

12.

Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:13–28PubMedCrossRef

13.

Huppertz A, Breuer J, Fels LM, Schultze-Mosgau M, Sutter G, Klein S et al (2011) Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP). J Magn Reson Imaging 33:409–16PubMedCrossRef

14.

Leonhardt M, Keiser M, Oswald S, Kuhn J, Jia J, Grube M et al (2010) Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38:1024–8PubMedCrossRef

15.

Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K et al (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44:793–8PubMedCrossRef

16.

van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE (1999) Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290:153–7PubMed

17.

Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–92PubMed

18.

Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, Weinmann HJ (2002) Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 37:680–4PubMedCrossRef

19.

Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M et al (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging–correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255:824–33PubMedCrossRef

20.

Giovanoli O, Heim M, Terracciano L, Bongartz G, Ledermann HP (2008) MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients. AJR Am J Roentgenol 190:W290–3PubMedCrossRef

21.

Rebouissou S, Bioulac-Sage P, Zucman-Rossi J (2008) Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 48:163–70PubMedCrossRef

22.

Flejou JF, Barge J, Menu Y, Degott C, Bismuth H, Potet F et al (1985) Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 89:1132–8PubMed

23.

Arrive L, Flejou JF, Vilgrain V, Belghiti J, Najmark D, Zins M et al (1994) Hepatic adenoma: MR findings in 51 pathologically proved lesions. Radiology 193:507–12PubMed

24.

Chung KY, Mayo-Smith WW, Saini S, Rahmouni A, Golli M, Mathieu D (1995) Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 165:303–8PubMed

25.

Grazioli L, Morana G, Kirchin MA, Schneider G (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 236:166–77PubMedCrossRef

26.

Hussain SM, van den Bos IC, Dwarkasing RS, Kuiper JW, den Hollander J (2006) Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis. Eur Radiol 16:1873–86PubMedCrossRef

27.

Paulson EK, McClellan JS, Washington K, Spritzer CE, Meyers WC, Baker ME (1994) Hepatic adenoma: MR characteristics and correlation with pathologic findings. AJR Am J Roentgenol 163:113–6PubMed

28.

van Aalten SM, Thomeer MG, Terkivatan T, Dwarkasing RS, Verheij J, de Man RA et al (2011) Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology 261:172–81PubMedCrossRef

29.

Vetelainen R, Erdogan D, de Graaf W, ten Kate F, Jansen PL, Gouma DJ et al (2008) Liver adenomatosis: re-evaluation of aetiology and management. Liver Int 28:499–508PubMedCrossRef

30.

Lewin M, Handra-Luca A, Arrive L, Wendum D, Paradis V, Bridel E et al (2006) Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology 241:433–40PubMedCrossRef

31.

Ricci P, Cantisani V, D'Onofrio M, Sahani D, Pagliara E, Calliada F et al (2008) Behavior of hepatocellular adenoma on real-time low-mechanical index contrast-enhanced ultrasonography with a second-generation contrast agent. J Ultrasound Med 27:1719–26PubMed

32.

Bioulac-Sage P, Balabaud C, Zucman-Rossi J (2010) Focal nodular hyperplasia, hepatocellular adenomas: past, present, future. Gastroenterol Clin Biol 34:355–8PubMedCrossRef

33.

Bioulac-Sage P, Balabaud C, Zucman-Rossi J (2010) Subtype classification of hepatocellular adenoma. Dig Surg 27:39–45PubMedCrossRef

34.

Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J (2007) Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 13:2649–54PubMed

35.

Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A et al (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50:481–9PubMedCrossRef

36.

Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A et al (2007) Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46:740–8PubMedCrossRef

Titel: Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI
verfasst von: Timm Denecke
Ingo G. Steffen
Sheela Agarwal
Daniel Seehofer
Thomas Kröncke
Enrique Lopez Hänninen
Incken-Birthe Kramme
Peter Neuhaus
Sanjay Saini
Bernd Hamm
Christian Grieser
Publikationsdatum: 01.08.2012
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 8/2012
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-012-2422-5

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI

Abstract

Objective

Methods

Results

Conclusions

Key Points

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2012

DNA double-strand breaks as potential indicators for the biological effects of ionising radiation exposure from cardiac CT and conventional coronary angiography: a randomised, controlled study

Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer

Electro-mechanical characteristics of myocardial infarction border zones and ventricular arrhythmic risk: novel insights from grid-tagged cardiac magnetic resonance imaging

Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes

Quantitative evaluation of MR perfusion imaging using blood pool contrast agent in subjects without pulmonary diseases and in patients with pulmonary embolism

Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie